Covis pharma

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

News

Covis Buys US Biotech Amag Pharmaceuticals

Specialty pharma company Covis has agreed to buy US-based Amag Pharmaceuticals, boosting its portfolio of therapies for life-threatening conditions and chronic illnesses.

News

AstraZeneca Sells Synagis Rights to Sobi

Top-Feature

Concept Heidelberg

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

AstraZeneca

Covis pharma

AstraZeneca Sells COPD Drug Rights to Covis

Covis Buys US Biotech Amag Pharmaceuticals

AstraZeneca Sells Synagis Rights to Sobi

Top-Feature

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Welcome to the World of Laboratories: Analytica 2026

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Anchored in Sustainability

Leading Transformation

API Manufacturing

Brenntag Downsizes Management Board, Retains Both Divisions

Leading the way. Driving results.

Advanced Recycling Conference 2025: New Paths to the Circular Economy

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

Newsletter & e-edition